{"article_link": "https://doi.org/10.1038/s41586-021-04278-5", "data": [{"id": "data_1", "omics": "Genomics", "link": "", "format": "Processed Data", "source": "European Genome-Phenome Archive (EGA)", "public_id": "EGAS00001004582", "description": "Whole Exome Sequencing (WES) and shallow Whole Genome Sequencing (sWGS) data used to identify somatic mutations, copy number alterations, and mutational signatures."}, {"id": "data_2", "omics": "Transcriptomics", "link": "", "format": "Processed Data", "source": "European Genome-Phenome Archive (EGA)", "public_id": "EGAS00001004582", "description": "RNA sequencing (RNA-seq) data used for differential gene expression analysis, gene set enrichment, and identification of gene expression profiles."}, {"id": "data_3", "omics": "Digital Pathology", "link": "", "format": "Processed Data", "source": "Cambridge University Hospitals NHS Foundation Trust", "public_id": "", "description": "Digital pathology data from pre-therapy biopsies, including lymphocyte density and immune infiltration assessments.", "label": {"RCB class": ["pCR", "RCB-I", "RCB-II", "RCB-III"]}}], "analyses": [{"id": "analysis_1", "analysis_name": "Differential analysis", "analysis_data": ["data_1", "data_2"], "label": {"RCB class": ["pCR", "RCB-I", "RCB-II", "RCB-III"]}, "description": "Differential expression and genomic analyses identified genes (e.g., TP53, PIK3CA) and genomic features associated with residual cancer burden (RCB) classes."}, {"id": "analysis_2", "analysis_name": "Gene set enrichment analysis", "analysis_data": ["data_2"], "label": {"RCB class": ["pCR", "RCB-I", "RCB-II", "RCB-III"]}, "description": "MSigDB Hallmark and Reactome gene sets (e.g., G2M checkpoint, IFNγ response) were used to identify pathways enriched in responders and non-responders. Specifically, 'Proliferation' and 'Immune activation' pathways were associated with response to therapy."}, {"id": "analysis_3", "analysis_name": "Copy number calling", "analysis_data": ["data_1"], "label": {"RCB class": ["pCR", "RCB-I", "RCB-II", "RCB-III"]}, "description": "Copy number alterations and chromosomal instability were analyzed to assess their association with residual cancer burden (RCB)."}, {"id": "analysis_4", "analysis_name": "Mutational signature decomposition", "analysis_data": ["data_1"], "label": {"RCB class": ["pCR", "RCB-I", "RCB-II", "RCB-III"]}, "description": "Mutational signatures were decomposed using DeconstructSigs to assess their association with RCB classes, specifically focusing on HRD and APOBEC signatures."}, {"id": "analysis_5", "analysis_name": "HLA typing and neoantigen calling", "analysis_data": ["data_1", "data_2"], "description": "HLA typing and neoantigen calling were performed to evaluate immune evasion mechanisms, with neoantigens below a binding affinity threshold of 500 nM retained for analysis and associated with poor response."}, {"id": "analysis_6", "analysis_name": "iC10 classification", "analysis_data": ["data_1", "data_2"], "label": {"RCB class": ["pCR", "RCB-I", "RCB-II", "RCB-III"]}, "description": "Tumors were classified into iC10 subtypes to assess their association with treatment response."}, {"id": "analysis_7", "analysis_name": "Machine learning model", "analysis_data": ["data_1", "data_2", "data_3"], "label": {"RCB class": ["pCR", "RCB-I", "RCB-II", "RCB-III"]}, "description": "An ensemble machine learning model integrated clinical, DNA, RNA, and digital pathology data. The model demonstrated an AUC of 0.87 in an external validation cohort."}], "results": [{"analysis_id": "analysis_1", "metrics": "P-value", "value": "< 0.05", "features": ["TP53 mutations", "PIK3CA mutations", "Tumor mutation burden", "Chromosomal instability"], "description": "Differential expression and genomic analyses identified statistically significant associations (P < 0.05) between TP53/PIK3CA mutations, tumor mutation burden, and chromosomal instability with RCB classes."}, {"analysis_id": "analysis_2", "metrics": "Normalized enrichment score", "value": "-2 to 2", "features": ["Proliferation", "Immune activation", "G2M checkpoint", "IFNγ response"], "description": "MSigDB Hallmark and Reactome pathways, particularly 'Proliferation', 'Immune activation', 'G2M checkpoint', and 'IFNγ response', showed significant enrichment in responders and non-responders."}, {"analysis_id": "analysis_3", "metrics": "Monotonic association", "value": "P = 0.0002", "features": ["Copy number alterations", "Chromosomal instability"], "description": "Copy number alterations and chromosomal instability showed a monotonic association with residual cancer burden (RCB), indicating a negative relationship with treatment response."}, {"analysis_id": "analysis_4", "metrics": "P-value", "value": "0.00001", "features": ["HRD score", "APOBEC signature"], "description": "HRD score and APOBEC signature exhibited a strong monotonic association with treatment response."}, {"analysis_id": "analysis_5", "metrics": "Binding affinity score", "value": "< 500 nM", "features": ["Neoantigens"], "description": "Neoantigens with binding affinity scores < 500 nM were identified as potential immune evasion markers associated with poor response."}, {"analysis_id": "analysis_6", "metrics": "Association", "value": "Overrepresentation", "features": ["iC10 subtypes"], "description": "Certain iC10 subtypes were overrepresented in specific RCB classes, with statistical significance indicating their role in treatment response."}, {"analysis_id": "analysis_7", "metrics": "AUC", "value": "0.87", "features": ["Clinical features", "DNA features", "RNA features", "Digital pathology features", "Lymphocyte density", "Immune cytolytic activity"], "description": "The external validation AUC of 0.87 confirms the robustness of the machine learning model in predicting pCR."}]}